Literature DB >> 22733133

The p53 isoform, Δ133p53α, stimulates angiogenesis and tumour progression.

H Bernard1, B Garmy-Susini, N Ainaoui, L Van Den Berghe, A Peurichard, S Javerzat, A Bikfalvi, D P Lane, J C Bourdon, A-C Prats.   

Abstract

The tumour suppressor p53, involved in DNA repair, cell cycle arrest and apoptosis, also inhibits blood vessel formation, that is, angiogenesis, a process strongly contributing to tumour development. The p53 gene expresses 12 different proteins (isoforms), including TAp53 (p53 (or p53α), p53β and p53γ) and Δ133p53 isoforms (Δ133p53α, Δ133p53β and Δ133p53γ). The Δ133p53α isoform was shown to modulate p53 transcriptional activity and is overexpressed in various human tumours. However, its role in tumour progression is still unexplored. In the present study, we examined the involvement of Δ133p53 isoforms in tumoural angiogenesis and tumour growth in the highly angiogenic human glioblastoma U87. Our data show that conditioned media from U87 cells depleted for Δ133p53 isoforms block endothelial cell migration and tubulogenesis without affecting endothelial cell proliferation in vitro. The Δ133p53 depletion in U2OS osteosarcoma cells resulted in a similar angiogenesis blockade. Furthermore, using conditioned media from U87 cells ectopically expressing each Δ133p53 isoform, we determined that Δ133p53α and Δ133p53γ but not Δ133p53β, stimulate angiogenesis. Our in vivo data using the chicken chorio-allantoic membrane and mice xenografts establish that angiogenesis and growth of glioblastoma U87 tumours are inhibited upon depletion of Δ133p53 isoforms. By TaqMan low-density array, we show that alteration of expression ratio of Δ133p53 and TAp53 isoforms differentially regulates angiogenic gene expression with Δ133p53 isoforms inducing pro-angiogenic gene expression and repressing anti-angiogenic gene expression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22733133     DOI: 10.1038/onc.2012.242

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

1.  p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration.

Authors:  C Turnquist; I Horikawa; E Foran; E O Major; B Vojtesek; D P Lane; X Lu; B T Harris; C C Harris
Journal:  Cell Death Differ       Date:  2016-04-22       Impact factor: 15.828

2.  Cancer-specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis.

Authors:  Marco M Candeias; Masatoshi Hagiwara; Michiyuki Matsuda
Journal:  EMBO Rep       Date:  2016-10-04       Impact factor: 8.807

3.  p53 isoform Δ113p53/Δ133p53 promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage.

Authors:  Lu Gong; Hongjian Gong; Xiao Pan; Changqing Chang; Zhao Ou; Shengfan Ye; Le Yin; Lina Yang; Ting Tao; Zhenhai Zhang; Cong Liu; David P Lane; Jinrong Peng; Jun Chen
Journal:  Cell Res       Date:  2015-02-20       Impact factor: 25.617

4.  Expression of p53β and Δ133p53 isoforms in different gastric tissues.

Authors:  Wansheng Ji; Na Zhang; Hongmei Zhang; Jingrong Ma; Hua Zhong; Jianxin Jiao; Zhixing Gao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  The Δ133p53 isoform and its mouse analogue Δ122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2.

Authors:  I Roth; H Campbell; C Rubio; C Vennin; M Wilson; A Wiles; G Williams; A Woolley; P Timpson; M V Berridge; N Fleming; M Baird; A W Braithwaite
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

6.  Hypothalamic apelin/reactive oxygen species signaling controls hepatic glucose metabolism in the onset of diabetes.

Authors:  Anne Drougard; Thibaut Duparc; Xavier Brenachot; Lionel Carneiro; Alexandra Gouazé; Audren Fournel; Lucie Geurts; Thomas Cadoudal; Anne-Catherine Prats; Luc Pénicaud; Didier Vieau; Jean Lesage; Corinne Leloup; Alexandre Benani; Patrice D Cani; Philippe Valet; Claude Knauf
Journal:  Antioxid Redox Signal       Date:  2013-09-18       Impact factor: 8.401

Review 7.  p53 Isoforms: Key Regulators of the Cell Fate Decision.

Authors:  Sebastien M Joruiz; Jean-Christophe Bourdon
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

8.  Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors.

Authors:  Amy L Sherborne; Vincent Lavergne; Katharine Yu; Leah Lee; Philip R Davidson; Tali Mazor; Ivan V Smirnoff; Andrew E Horvai; Mignon Loh; Steven G DuBois; Robert E Goldsby; Joseph P Neglia; Sue Hammond; Leslie L Robison; Rosanna Wustrack; Joseph F Costello; Alice O Nakamura; Kevin M Shannon; Smita Bhatia; Jean L Nakamura
Journal:  Clin Cancer Res       Date:  2016-09-28       Impact factor: 12.531

Review 9.  A mouse model of the Δ133p53 isoform: roles in cancer progression and inflammation.

Authors:  Marina Kazantseva; Sunali Mehta; Ramona A Eiholzer; Noelyn Hung; Anna Wiles; Tania L Slatter; Antony W Braithwaite
Journal:  Mamm Genome       Date:  2018-07-10       Impact factor: 2.957

10.  A functional interplay between Δ133p53 and ΔNp63 in promoting glycolytic metabolism to fuel cancer cell proliferation.

Authors:  Lu Gong; Xiao Pan; Chuan-Bian Lim; Anna de Polo; John B Little; Zhi-Min Yuan
Journal:  Oncogene       Date:  2018-01-26       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.